Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment reporting

Analytics

Phase 2
2(66.7%)
Phase 4
1(33.3%)
3Total
Phase 2(2)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
SYF1b813f52676b4e8c82d2b62df97fffd8Phase 4Recruiting

Patient- and care-related benefits of amyloid PET imaging (ENABLE)

Role: lead

SYF61cb079a808d420c8d0daf473349cc3bPhase 2Not Yet Recruiting

A double-blinded, randomized, placebo-controlled, multi-center trial of Efgartigimod in autoimmune dementia (EfgaDem)

Role: lead

SYFecbf3ea531a345cfacae844bb868d772Phase 2Recruiting

Evaluation of the efficacy and safety of Rituximab in patients with Amyotrophic Lateral Sclerosis (ALS)

Role: lead

All 3 trials loaded